Similar Natural Products in NPASS
Similarity level is defined by Tanimoto coefficient (Tc) between two molecules. Tc lies between [0, 1] where '1' indicates the highest similarity. What is Tanimoto coefficient
●  The left chart: Distribution of similarity level between NPC326364 and all remaining natural products in the NPASS database.
●  The right table: Most similar natural products (Tc>=0.56 or Top200).
range |
Tanimoto Coefficient |
0-0.1 | 17683 |
0.1-0.2 | 9657 |
0.2-0.3 | 1949 |
0.3-0.4 | 1210 |
0.4-0.5 | 309 |
0.5-0.6 | 65 |
0.6-0.7 | 9 |
0.7-0.8 | 4 |
0.8-0.85 | 2 |
0.85-0.9 | 0 |
0.9-0.95 | 1 |
0.95-1 | 0 |
  Similar Clinical/Approved Drugs
Similarity level is defined by Tanimoto coefficient (Tc) between two molecules.
●  The left chart: Distribution of similarity level between NPC326364 and all drugs/candidates.
●  The right table: Most similar clinical/approved drugs (Tc>=0.56 or Top200).
range |
Tanimoto Coefficient |
0-0.1 | 949 |
0.1-0.2 | 3450 |
0.2-0.3 | 2362 |
0.3-0.4 | 1505 |
0.4-0.5 | 746 |
0.5-0.6 | 123 |
0.6-0.7 | 17 |
0.7-0.8 | 5 |
0.8-0.85 | 2 |
0.85-0.9 | 0 |
0.9-0.95 | 2 |
0.95-1 | 0 |
Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.9011 |
High Similarity |
NPD9193 |
Approved |
0.9011 |
High Similarity |
NPD9194 |
Approved |
0.8333 |
Intermediate Similarity |
NPD8565 |
Clinical (unspecified phase) |
0.81 |
Intermediate Similarity |
NPD8571 |
Phase 3 |
0.7387 |
Intermediate Similarity |
NPD420 |
Discontinued |
0.7257 |
Intermediate Similarity |
NPD1734 |
Clinical (unspecified phase) |
0.7255 |
Intermediate Similarity |
NPD8566 |
Approved |
0.7075 |
Intermediate Similarity |
NPD9071 |
Phase 3 |
0.7009 |
Intermediate Similarity |
NPD2191 |
Discontinued |
0.675 |
Remote Similarity |
NPD1705 |
Discontinued |
0.6721 |
Remote Similarity |
NPD3678 |
Phase 2 |
0.6667 |
Remote Similarity |
NPD4763 |
Clinical (unspecified phase) |
0.6581 |
Remote Similarity |
NPD306 |
Approved |
0.656 |
Remote Similarity |
NPD2602 |
Clinical (unspecified phase) |
0.6406 |
Remote Similarity |
NPD4765 |
Approved |
0.6406 |
Remote Similarity |
NPD4764 |
Approved |
0.6364 |
Remote Similarity |
NPD9366 |
Approved |
0.632 |
Remote Similarity |
NPD1264 |
Phase 2 |
0.6308 |
Remote Similarity |
NPD2618 |
Phase 1 |
0.6091 |
Remote Similarity |
NPD8861 |
Approved |
0.6091 |
Remote Similarity |
NPD8859 |
Approved |
0.6091 |
Remote Similarity |
NPD8862 |
Approved |
0.6074 |
Remote Similarity |
NPD1988 |
Phase 1 |
0.6048 |
Remote Similarity |
NPD8832 |
Approved |
0.6036 |
Remote Similarity |
NPD8836 |
Approved |
0.6029 |
Remote Similarity |
NPD4709 |
Approved |
0.5968 |
Remote Similarity |
NPD8826 |
Approved |
0.5899 |
Remote Similarity |
NPD427 |
Approved |
0.5899 |
Remote Similarity |
NPD162 |
Approved |
0.5899 |
Remote Similarity |
NPD428 |
Approved |
0.5899 |
Remote Similarity |
NPD426 |
Approved |
0.5896 |
Remote Similarity |
NPD174 |
Discontinued |
0.5878 |
Remote Similarity |
NPD799 |
Phase 1 |
0.5775 |
Remote Similarity |
NPD491 |
Approved |
0.5769 |
Remote Similarity |
NPD8827 |
Approved |
0.5758 |
Remote Similarity |
NPD8584 |
Approved |
0.5734 |
Remote Similarity |
NPD5969 |
Clinical (unspecified phase) |
0.5714 |
Remote Similarity |
NPD757 |
Phase 3 |
0.5714 |
Remote Similarity |
NPD2140 |
Approved |
0.5714 |
Remote Similarity |
NPD2142 |
Approved |
0.5714 |
Remote Similarity |
NPD2141 |
Approved |
0.5657 |
Remote Similarity |
NPD8186 |
Phase 1 |
0.5657 |
Remote Similarity |
NPD8185 |
Discontinued |
0.5655 |
Remote Similarity |
NPD5300 |
Clinical (unspecified phase) |
0.5606
|
Remote Similarity |
NPD809 |
Discontinued |